This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A recent Nature Medicine research report is sounding an alarm. The risk of developing dementia by the age of 95 is 42%. The finding that the risk of dementia increases with age is well described. What’s new and startling about this result is the number. It’s double prior estimates. The investigator team, led by researchers at New York University and funded by the National Institutes of Health, reported even higher risk estimates for women, people who self-report Black racial identi
January 14, 2025: “AskBio Inc, a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first participants have been randomized in its Phase II clinical trial in patients with Parkinsons disease (PD). The randomization of the first participants in REGENERATE-PD is positive news for people living with Parkinsons disease and the physicians treating them, said Dr Rajesh Pahwa, MD, Director, Parkinson’s Disease and Movement Disorder C
After several years of investigation, the U.S. Department of Justice filed a civil lawsuit accusing Walgreens of illegally dispensing millions of prescriptions for opioid painkillers and failing to fulfill its role as a critical gatekeeper in the nation’s health care system. The lawsuit is only the latest to blame one of the largest pharmacy chains in the U.S. for contributing to a long-running opioid crisis that has led to the death of hundreds of thousands of Americans.
January 15, 2025 : “Johnson & Johnsonannounced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration for TAR-200 for the treatment of patients with Bacillus Calmette-Gurin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
The likely next secretary of state, Sen. Marco Rubio, once said of the World Health Organization: “The WHO is a corrupt, radical institution that was powerless to stop Covid-19 spreading beyond China.” That was in 2022. In 2020, at the height of the Covid-19 pandemic, then-President Trump pulled U.S. funding and membership from the WHO, also slinging accusations of pandemic mismanagement.
India’s clinical trials landscape is poised for significant transformation in 2025, with technological innovation and patient-guided approaches reshaping the industry. As the country strengthens its position in global pharmaceutical research, several key trends are expected to drive growth and evolution in the clinical trials sector. Increase in Phase 1 Clinical Trials India is set to emerge as a powerhouse in early-phase clinical research, particularly in Phase 1 trials.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
357 
Let's personalize your content